title: Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia.
abstract: OBJECTIVE
  This study examined whether the increase of adiponectin associated with extended-release (ER) niacin/laropiprant combination attenuates the adverse effect of niacin on glucose and insulin resistance in Hong Kong Chinese patients with dyslipidaemia.
  
  
  METHODS
  Patients (N = 121) were treated with ER niacin/laropiprant 1 g/20 mg for 4 weeks and then the dose was doubled for an additional 8 weeks. Measurements of fasting lipids, glucose, insulin, and adiponectin were performed at baseline and during the study.
  
  
  RESULTS
  There were significant (P < 0.001) increases in glucose (9.4 ± 13.1%), insulin (70.2 ± 91.0%), HOMA-IR (87.8 ± 103.9%), and adiponectin (169.3 ± 111.6%). The increase in adiponectin was significantly associated with increase in glucose (r = 0.221, P < 0.05), insulin (r = 0.184, P < 0.05), and HOMA-IR (r = 0.237, P < 0.01) and the association remained significant after adjustment for changes in body weight or body fat mass.
  
  
  CONCLUSIONS
  Treatment with ER niacin/laropiprant led to a significant increase in adiponectin levels but worsening of glucose levels and insulin resistance, and the increase in adiponectin and insulin resistance were correlated suggesting the increase in adiponectin did not ameliorate the deterioration in insulin resistance. Clinical trial is registered with number on WHO-ICTRP: ChiCTR-ONC-10001038.
authors.affiliation: Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong.
authors.forename: Miao
authors.identifier: 0000-0001-5403-4095
authors.initials: M
authors.lastname: Hu
authors.affiliation: Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong ; Diabetes Center, Second Xiangya Hospital, Institute of Metabolism and Endocrinology, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, Changsha, Hunan 410013, China.
authors.forename: Ya-Ling
authors.initials: YL
authors.lastname: Yang
authors.affiliation: Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
authors.forename: Daisaku
authors.initials: D
authors.lastname: Masuda
authors.affiliation: Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
authors.forename: Shizuya
authors.initials: S
authors.lastname: Yamashita
authors.affiliation: Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong.
authors.forename: Brian
authors.initials: B
authors.lastname: Tomlinson
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000378:metabolism; D002681:China; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000627:therapeutic use*; D014803:Vitamin B Complex / Q000494:pharmacology*
chemical_list: D052242:Adiponectin; D001786:Blood Glucose; D000960:Hypolipidemic Agents; D007211:Indoles; D007328:Insulin; C518174:MK-0524; D014803:Vitamin B Complex; D009525:Niacin